Loading…
Kiniksa Pharmaceuticals International, plc is projected to rise to $90.47 by 2027, a +43% move from its current price of $63.44. KNSA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $61.86 | $63.50 | $65.18 | +0.09% |
| Jul 14 | $61.24 | $63.55 | $65.95 | +0.18% |
| Jul 15 | $60.79 | $63.61 | $66.56 | +0.26% |
| Jul 16 | $60.42 | $63.66 | $67.08 | +0.35% |
| Jul 17 | $60.10 | $63.72 | $67.56 | +0.44% |
| Jul 18 | $59.82 | $63.77 | $67.99 | +0.53% |
| Jul 19 | $59.56 | $63.83 | $68.40 | +0.61% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $59.56 | $63.83 | $68.40 | +0.61% |
| Week 2 | $58.23 | $64.22 | $70.83 | +1.23% |
| Week 3 | $57.32 | $64.62 | $72.85 | +1.85% |
| Week 4 | $56.61 | $65.01 | $74.67 | +2.48% |
| Week 5 | $56.03 | $65.41 | $76.36 | +3.11% |
| Week 6 | $55.55 | $65.81 | $77.98 | +3.74% |
| Week 7 | $55.14 | $66.22 | $79.53 | +4.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company that develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. It offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Kiniksa Pharmaceuticals International, plc (KNSA) is the asset. It is currently priced at $67.29 per share. Its market capitalization is $5.18B and it ranks 1352. The near-term price picture is informed by a 30-day range of $56.55 to $80.07, with a bullish longer-term forecast.
The year-by-year forecast shows substantial upside, with the average price advancing from $67.29 in 2026 to $100.29 in 2027 and then higher through 2030, 2040, and 2050. By 2030 the average price is $184.59 with an ROI of 174.3%, by 2040 $571.37 with an ROI of 749.1%, and by 2050 $1,553.70 with an ROI of 2,209%. The sentiment is bullish across the longer horizon, indicating strong growth potential as projected by the forecast.
A major floor 38.8% below — a decisive break under it would weaken the trend.
The nearest floor, 26.0% below — buyers have tended to step in here.
The nearest ceiling, 6.1% above — a clean break opens room to run.
A major ceiling 25.5% above — clearing it would confirm fresh momentum.
Key KNSA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KNSA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $64.73 | Sell | $64.28 | Sell |
| MA 10 | $63.66 | Sell | $63.04 | Buy |
| MA 20 | $59.33 | Buy | $60.26 | Buy |
| MA 50 | $55.78 | Buy | $55.83 | Buy |
| MA 100 | $50.91 | Buy | $51.87 | Buy |
| MA 200 | $45.79 | Buy | $46.37 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.67 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 62.83 | Neutral |
| Williams %R (14) | -37.02 | Info |
| MACD (12,26,9) | 0.41 | Buy |
| ROC (12) | 6.64 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 62.98 | Neutral |
| TRIX (15) | 0.78 | Buy |
| Awesome (5,34) | 9.28 | Buy |
| Ultimate (7,14,28) | 55.87 | Neutral |
| Momentum (10) | 6.55 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 65.49 | Sell |
| ADX (14) | 30.16 | Buy |
| ATR (14) | 1.65 | Info |
The near-term technical picture is bullish. RSI14 is 70, indicating strong momentum. The stock is trading above the 50-day moving average of $54.71 and the 200-day moving average of $45.36, suggesting positive intermediate-term momentum.
Support is at $46.92 and resistance at $67.29, with a 30-day price range from $56.55 to $80.07. This setup points to potential upside toward the upper end of the range, while a dip toward the support level could occur if momentum wanes.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $37.92 | $63.44 | $90.05 | 0% | Neutral | |
| $72.31 | $90.47 | $119.58 | +43% | Bullish | |
| $94.09 | $120.90 | $165.59 | +91% | Bullish | |
| $110.02 | $144.52 | $203.56 | +128% | Bullish | |
| $121.59 | $162.85 | $234.82 | +157% | Bullish | |
| $132.24 | $180.28 | $265.35 | +184% | Bullish | |
| $140.52 | $194.74 | $291.96 | +207% | Bullish | |
| $164.20 | $231.09 | $352.29 | +264% | Bullish | |
| $188.69 | $269.48 | $417.18 | +325% | Bullish | |
| $216.76 | $313.92 | $492.97 | +395% | Bullish | |
| $299.31 | $461.84 | $770.00 | +628% | Bullish | |
| $710.34 | $1,221.69 | $2,222.95 | +18.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $37.92 | $63.44 | $75.69 | +0.00% |
| August 2026 | $55.04 | $64.88 | $78.49 | +2.28% |
| September 2026 | $57.89 | $68.71 | $84.01 | +5.90% |
| October 2026 | $59.35 | $70.84 | $87.40 | +3.10% |
| November 2026 | $58.67 | $70.38 | $87.49 | -0.65% |
| December 2026 | $59.70 | $71.94 | $90.05 | +2.21% |
Click any year to see its month-by-month KNSA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, KNSA could reach as high as $90.05, with a base case around $63.44 and support toward $37.92 — roughly 0% from $63.44. Price action looks broadly range-bound.
Expect KNSA to range from $72.31 to $119.58 through 2027. The $90.47 average target implies a +43% move from current prices. That is up +43% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The KNSA price prediction for 2028 points to an average of $120.90 (low $94.09, high $165.59) — a potential gain of +91% on today's $63.44. Momentum favours further upside here.
In 2029, KNSA is projected to trade between $110.02 and $203.56, averaging $144.52 — a potential gain of +128% from today's $63.44. That is up +20% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Kiniksa Pharmaceuticals International, plc's 2030 outlook centres on $162.85, within a $121.59 to $234.82 range. That is up +13% on the projected 2029 average. That marks a +157% change versus current levels. Momentum favours further upside here.
By 2031, KNSA could reach as high as $265.35, with a base case around $180.28 and support toward $132.24 — roughly +184% from $63.44. Buyers look set to stay in control over this stretch.
Expect KNSA to range from $140.52 to $291.96 through 2032. The $194.74 average target implies a +207% move from current prices. That is up +8% on the projected 2031 average. Momentum favours further upside here.
The KNSA price prediction for 2033 points to an average of $231.09 (low $164.20, high $352.29) — a potential gain of +264% on today's $63.44. Buyers look set to stay in control over this stretch.
In 2034, KNSA is projected to trade between $188.69 and $417.18, averaging $269.48 — a potential gain of +325% from today's $63.44. That is up +17% on the projected 2033 average. Momentum favours further upside here.
Kiniksa Pharmaceuticals International, plc's 2035 outlook centres on $313.92, within a $216.76 to $492.97 range. That is up +16% on the projected 2034 average. That marks a +395% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, KNSA could reach as high as $770.00, with a base case around $461.84 and support toward $299.31 — roughly +628% from $63.44. Momentum favours further upside here.
Expect KNSA to range from $710.34 to $2,222.95 through 2050. The $1,221.69 average target implies a +18.3x move from current prices. That is up +165% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in KNSA today (≈ 15.762926 KNSA) could be worth
$19,257.46
+$18,257.46 (+1826%) by 2050 · US Dollar
Based on the average projected KNSA price of $1,221.69 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KNSAwould be worth at today's price.
$1,000 invested in KNSA on Jul 10, 2025 (≈ 34.542313 KNSA) would be worth
$2,191.36
+$1,191.36 (+119.1%) today · 2.19× · US Dollar
Based on a KNSA entry price of $28.95 vs. today's $63.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $64.53 | $983.11 | -1.7% |
| 1 month ago | $49.27 | $1,287.6 | +28.8% |
| 3 months ago | $47.08 | $1,347.49 | +34.7% |
| 6 months ago | $41.12 | $1,542.8 | +54.3% |
| 1 year ago | $28.95 | $2,191.36 | +119.1% |
| All time (5.0y) ago | $13.82 | $4,590.45 | +359.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KNSA forecast.
Our base-case forecast reaches $130.00 around 2029.
Implied market cap at $130.00: $6.02B
The multi-year forecast points to a continuing bullish trajectory with rising averages and sizable ROI. By 2030, the average price is $184.59 and the ROI is 174.3%. By 2040, the average price is $571.37 and the ROI is 749.1%.
By 2050, the average price is $1,553.70 and the ROI is 2,209%. The long-range outlook thus shows strong upside potential, but these are estimates and not guarantees. Investors should consider that outcomes can differ from forecasted values and that market conditions can change.
Tap a question to reveal the answer.
Avg $184.59; Min $137.60; Max $266.69; ROI 174.3%; Sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising average prices and positive ROI (e.g., 2027 avg $100.29, ROI 49%; 2030 avg $184.59, ROI 174.3%), though 2026 is neutral and projections are estimates.
Yes. The 2027 forecasted average price is $100.29, with a 2027 min of $80.06 and max of $132.76; sentiment is BULLISH.
Avg $1,553.70; Min $899.41; Max $2,836.15; ROI 2,209%; Sentiment BULLISH.
Current price is $67.29. The 30-day range is $56.55 to $80.07, with support at $46.92 and resistance at $67.29; RSI14 is 70; 50-day SMA is $54.71 and 200-day SMA is $45.36.
Kiniksa Pharmaceuticals International, plc Community Discussion
0Share your Kiniksa Pharmaceuticals International, plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.